Recommend: 0
-
01-30-2019, 02:12 PM #1
IGF 1 And MK-677 Used In Clinical Trial For Treatment of CNS Disorders
IGF 1 lr3 as we know is a fantastic growth factor for bodybuilders and athletes of all kinds. Used for Building quality lean muscle mass, as well as for its ability to keep you lean by way of signa;ling the body to burn fat for energy. We have also read and posted many studies here at MuscleChemistry regarding Insulin-like growth factor 1 healing power and regenerative capabilities on tendons and cartlidge and it promotes collagen synthesis as well. But lately I have been reading a ton on IGF 1 treatment for Central Nervous System Disorders.
So Enjoy:
The therapeutic potential of IGF-1 was found to be relevant to the treatment of several CNS disorders, most notably Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, and autism spectrum disorder. Table 1 categorizes the human clinical trials in specific CNS diseases.
Table 1
Clinical Trials with IGF-1 in CNS DisordersOverview of clinical trials using IGF-1 as a therapeutic agent in CNS disorders to date
Intervention Author
and YearSample
SizeStudy
DesignDuration
of
TreatmentPrimary
Outcome
MeasureOutcome Multiple
SclerosisrhIGF-1 (J. A. Frank et al., 2002) 7 Open-label
crossover6 months Contrast
enhancing lesion
frequency on
MRINegative Amyotrophic
Lateral
SclerosisrhIGF-1 (Nagano, Shiote, et al., 2005) 9 Double-
blind,
randomized
clinical9 months Norris Scales Positive Amyotrophic
Lateral
SclerosisrhIGF-1 (Lai et al., 1997) 141 Double
blind,
placebo
controlled,
parallel
group9 months Appel
Amyotrophic
Lateral Sclerosis
rating scalePositive Amyotrophic
Lateral
SclerosisrhIGF-1 (Borasio et al., 1998) 183 Double
blind,
placebo
controlled,
parallel
group9 months Appel
Amyotrophic
Lateral Sclerosis
rating scaleNegative Amyotrophic
Lateral
SclerosisrhIGF-1 (Sorenson et al., 2008) 330 Double
blind,
placebo
controlled,
parallel
group2 years Rate of change
in the averaged
manual muscle
testing score
(MMT)Negative Alzheimer’s
DementiaMK-677 (Sevigny et al., 2008) 563 Double
blind,
placebo
controlled,
parallel
group12 months Clinician’s
Interview Based
Impression of
Change with
caregiver input
(CIBIC-plus)Negative Phelan-
McDermid
syndromerhIGF-1 (Kolevzon et al., 2014) 9 Double
blind,
placebo
controlled,
crossover3 months Aberrant
Behavior
Checklist-Social
Withdrawal
subscalePositive Rett
syndromerhIGF-1 (Khwaja et al., 2014) 9
(MAD)
12
(OLE)Unblind
multiple
ascending
dose and
open label
extension4 week
MAD
20 week
OLEMultiple
Cardiorespiratory
measuresPositive
Open in a separate windowAbbreviations: MK-677 = ibutamoren mesylate; MAD = multiple ascending dose; OLE = open-label extension
The extensive investigation of the effect of IGF-1 during development and the continued discovery of its diverse roles throughout the CNS exemplifies the presence of common underlying pathways responsible for neuronal development. Although many different genetic mutations and disrupted pathways lead to syndromes associated with ASD, there is significant overlap in their molecular and electrophysiological deficits. Specific deficits in synaptic function and plasticity in glutamate signaling have been consistently documented in various forms of ASD using mouse and human neuronal models and have been rescued with IGF-1. The link between synapse dysfunction and ASD suggest that treatment with IGF-1 may also have implications for ASD associated with disruptions in common underlying pathways. Preliminary studies in children with PMS and Rett syndrome have been successful, and IGF-1 may also be a promising therapeutic candidate in other single gene causes of ASD and perhaps in idiopathic ASD; a trial is underway with IGF-1 in ASD defined broadly (ClinicalTrials.gov Identifier: NCT01970345). Although definitive studies are needed, pilot data suggest the promise of IGF-1 in neurodevelopmental disorders associated with ASD.
Highlights- IGF-1 is necessary for proper development of the central nervous system
- IGF-1 dysregulation leads to neuronal dysfunction and severe developmental disorders
- IGF-1 may be a safe and potentially effective treatment for several CNS disorders
-
03-23-2019, 11:34 AM #2
Similar Threads
-
Dealing with Eating Disorders
By drtbear1967 in forum Female Fitness ForumReplies: 3Last Post: 06-28-2018, 04:29 AM -
Sex Chromosomes, Chromosome Disorders And Brain/Psychiatric Disorders (Area-1255 EXCLUSIVE!)
By Area 1255 in forum Bodybuilding Steroid & Training ArticlesReplies: 1Last Post: 04-24-2018, 03:39 PM -
synthetic REV-ERB ligands that pharmacologically target the circadian rhythm may be beneficial in the treatment of sleep disorders as well as metabolic diseases.
By Presser in forum Bodybuilding Steroid & Training ArticlesReplies: 0Last Post: 04-19-2018, 08:29 AM -
Experimental Drug Achieves Unprecedented Weight Loss, Clinical Trial Finds
By big in vegas in forum MuscleChemistry DiscussionReplies: 2Last Post: 04-13-2011, 07:13 PM -
Who would step up for a human clinical trial??
By The Dude in forum MuscleChemistry DiscussionReplies: 10Last Post: 08-11-2009, 07:37 PM